Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB099280 + Adagrasib in KRASG12C-Mutated Advanced Solid Tumors
NCT06039384Phase 1Terminated
- Sponsor
- Incyte
- Start
- Dec 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of incb099280 in solid tumor, non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (2 arms), sponsored by Incyte. Primary endpoints: Number of Participants With Dose-limiting Toxicities, Number of Participants With Treatment-emergent Adverse Events up to 574 days and 1 more. Started Dec 2023; status: terminated.
02
Drugs
incb099280
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06039384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06039384.